In conclusion, STAT3 mutations cause DNA hypermethylation resulting in sensitivity to DNMT inhibitors, which could be considered as a novel treatment option for LGLL patients with resistance to standard treatments. Here, DNMT1 is linked to T-cell large granular lymphocyte leukemia.